Kiniksa Pharmaceuticals International PLC
(NAS:KNSA)
$
22.53
0.92 (4.26%)
Market Cap: 1.60 Bil
Enterprise Value: 1.33 Bil
PE Ratio: 204.82
PB Ratio: 3.69
GF Score: 62/100 - Q1 2024 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptApr 23, 2024$17.68 (+3.42%)Earnings
- Q4 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 28, 2024$20.36 (-2.54%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptOct 31, 2023$15.25 (-2.74%)Earnings
- Q2 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptJul 25, 2023$19.48 (+30.39%)Earnings
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptMay 02, 2023$12.59 (+14.66%)Earnings
- Q4 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 28, 2023$12.86 (-3.45%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptNov 01, 2022$12.8 (+12.08%)Earnings
- Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptAug 03, 2022$10.68 (+7.12%)Earnings
- Q1 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptMay 03, 2022$10.11 (+7.44%)Earnings
- Q4 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 22, 2022$10.62 (-0.93%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Q3 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptNov 01, 2021$12.73 (+22.52%)Earnings
- Q2 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptAug 03, 2021$13.69 (-15.65%)Earnings
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Kiniksa Pharmaceuticals Ltd FDA Approval of ARCALYST (rilonacept) for Recurrent Pericarditis Conference Call TranscriptMar 18, 2021
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Kiniksa Pharmaceuticals Ltd Rilonacept Analyst Day TranscriptSep 29, 2020
- Kiniksa Pharmaceuticals Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Kiniksa Pharmaceuticals Ltd Annual Shareholders Meeting TranscriptJun 30, 2020
- Kiniksa Pharmaceuticals, Ltd. - Special Call TranscriptJun 29, 2020
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
- Kiniksa Pharmaceuticals Ltd at Barclays Global Healthcare Conference TranscriptMar 12, 2019
Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022 / 03:15PM GMT
Release Date Price:
$15.34
(-0.13%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Good morning. Welcome to the BofA SMID Cap Biotech Conference. My name is Geoff Meacham, I'm the Senior of Biopharma analyst, and welcome to the morning sessions. We're thrilled to have with us Kiniksa. Speaking on behalf of Kiniksa is CEO, Sanj Patel. Sanj, how are you?
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst
I'm fairly well, how are you, Geoff?
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Good. Good to see your face. Next year, maybe we'll do this in person. So let's just kick it off real quick. I know you're an efficient guy, so let's just go and give us a 30,000-foot view here of a quick background and then get right into some questions on our (inaudible) a lot of stuff.
Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board
Absolutely. So again, thanks for having me here, Geoff.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)